S&P Futures
4,013.00 -19.50 (-0.48%) Dow Futures
33,615.00 -170.00 (-0.50%) Nasdaq Futures
11,889.25 -78.75 (-0.66%) Russell 2000 Futures
1,886.40 -7.10 (-0.37%) Crude Oil
77.01 -0.89 (-1.14%) Gold
1,919.10 -20.10 (-1.04%)
Esperion Therapeutics, Inc. (ESPR)
After hours:
Chart Events
Performance Outlook
| Previous Close | 6.68 |
| Open | 6.67 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 900 |
| Day's Range | 6.43 - 6.69 |
| 52 Week Range | 3.28 - 8.87 |
| Volume | |
| Avg. Volume | 1,945,572 |
| Market Cap | 405.048M |
| Beta (5Y Monthly) | 0.21 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -5.22 |
| Earnings Date | Feb 20, 2023 - Feb 24, 2023 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 10.36 |
- Simply Wall St.
The past five years for Esperion Therapeutics (NASDAQ:ESPR) investors has not been profitable
Long term investing works well, but it doesn't always work for each individual stock. We really hate to see fellow...
- GlobeNewswire
RFK Announces Team-Wide Partnership with Esperion Therapeutics; Includes Primary Partnership for Brad Keselowski at the ’23 Daytona 500
NASCAR Champion Brad Keselowski to Run No. 6 NEXLIZET (bempedoic acid and ezetimibe) Ford in Famed Daytona 500CONCORD, N.C., Jan. 11, 2023 (GLOBE NEWSWIRE) -- RFK Racing has announced that Esperion Therapeutics, a Michigan-based pharmaceutical company, has partnered with the team for a multi-year agreement pursuant to which Esperion will promote two cholesterol lowering treatments – NEXLIZET (bempedoic acid and ezetimibe) and NEXLETOL (bempedoic acid). NEXLIZET will be featured on Keselowski’s N
- Zacks
PTC Therapeutics (PTCT) Soars 5.8%: Is Further Upside Left in the Stock?
PTC Therapeutics (PTCT) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
